.png)
Associate Professor David Croucher
University of New South Wales
$445,226
2025 - 2028
The Research
High-Risk Neuroblastoma is an aggressive and chemoresistant childhood cancer with very low survival rates.
Through our unique mathematical modelling approach, capable of providing simulations of chemotherapy response that scale from the patient-level down to single-cell resolution, we have now developed strategies capable of restoring the ability of neuroblastomas to respond to chemotherapy.
This innovative approach involves priming treatment naive tumours with the histone deacetylase (HDAC) inhibitor Belinostat, which sensitises these tumours to subsequent treatment with standard-of-care chemotherapy.
Our preliminary PDX model data demonstrates that Belinostat priming can double survival time in response to frontline chemotherapy. Therefore, we will now perform the pre-clinical assessment required to prepare these strategies for clinical trials.
.svg)
